S2 Genomics
S2 Genomics: Automating raw tissue processing into single cells for genomics studies.
Founded
2016S2 Genomics: Automating raw tissue processing into single cells for genomics studies.
Founded with the mission to revolutionize tissue processing for genomics and cell biology studies, S2 Genomics focuses on automating the conversion of raw tissues into single cells or nuclei. Their flagship product, the Singulator™ Automated Tissue Dissociation Platform, enables rapid and efficient tissue dissociation, supporting applications such as single-nucleus RNA sequencing (snRNA-Seq) from FFPE samples and ultra-low volume nuclei isolations. S2 Genomics aims to streamline workflows in research laboratories, enhancing the accuracy and efficiency of genomic studies.
S2 Genomics has garnered attention from notable figures in the biotechnology and genomics sectors, attracting significant investment to advance its innovative solutions. The company has achieved key milestones, including the successful deployment of the Singulator platform in various research institutions. By automating a traditionally labor-intensive process, S2 Genomics has significantly impacted the field of genomics, enabling more precise and high-throughput analysis of cellular and genetic material.
Companies similar to S2 Genomics include Singular Genomics, QuantumCyte, 10x Genomics and BioSkryb Genomics.
S2 Genomics was founded in 2016.
S2 Genomics' headquarters is located in Livermore, CA, US.
S2 Genomics' most recent funding round was for $16M (USD) in January 2024.
As of Jan 23, 2024, S2 Genomics has disclosed funding of $18.2M (USD). Undisclosed round amounts are excluded.
S2 Genomics has 26 employees as of Feb 5, 2024.
BioSkryb Genomics
bioskryb.com
